November 5, 2013

FDA approves second Alzheimer's PET agent

GE Healthcare announced that its PET imaging agent for Alzheimer’s has been approved for market by the U.S. Food and Drug Administration. Vizamyl (flutemetamol F 18 injection) is used to visually detect beta amyloid plaque, which is associated with Alzheimer’s and dementia, in the brains of patients being evaluated for the conditions.  {read more here}